Search research articles
Contact Us
Filters
Showing results (241-250 of 312) with videos related to
Page
of 32
Sort By:
The Journal of Urology
|
April 19, 2021
Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, et al.
The Journal of Urology
|
December 5, 2025
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
The Journal of Urology
|
December 9, 2025
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
Neal D Shore, Martin Gleave, Ugo De Giorgi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2024
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study
Neal D Shore, Karim Fizazi, Teuvo L J Tammela, et al.
Cancer Medicine
|
December 26, 2025
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS
Matthias Saar, Karim Fizazi, Neal D Shore, et al.
The Journal of Urology
|
December 21, 2016
Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Claus G Roehrborn, Steven N Gange, Marc C Gittelman, et al.
The Journal of Urology
|
October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data
E David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Urologic Oncology
|
May 4, 2020
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial
Neal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
Future Oncology (London, England)
|
June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Page
of 32
Search research articles
Search
Showing results (241-250 of 312) with videos related to
Sort By:
Page
of 32
The Journal of Urology
|
April 19, 2021
Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, et al.
The Journal of Urology
|
December 5, 2025
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
The Journal of Urology
|
December 9, 2025
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
Neal D Shore, Martin Gleave, Ugo De Giorgi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2024
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study
Neal D Shore, Karim Fizazi, Teuvo L J Tammela, et al.
Cancer Medicine
|
December 26, 2025
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS
Matthias Saar, Karim Fizazi, Neal D Shore, et al.
The Journal of Urology
|
December 21, 2016
Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Claus G Roehrborn, Steven N Gange, Marc C Gittelman, et al.
The Journal of Urology
|
October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data
E David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Urologic Oncology
|
May 4, 2020
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial
Neal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
Future Oncology (London, England)
|
June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Page
of 32